← Back to headlines
Merck Exceeds Q1 Estimates on Strong Oncology Demand
Merck reported first-quarter earnings that surpassed Wall Street estimates, driven by robust demand for its oncology drug Keytruda and other new products. The pharmaceutical giant also narrowed its full-year outlook, factoring in a significant charge related to a recent deal.
30 Apr, 10:32 — 30 Apr, 12:41
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (37/100)3 sources25/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left2
Left (2)
Yahoocnbc
Center
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 1 region4/34
US3
ℹAll sources from US region
Sources
Showing 2 of 3 sources
cnbcMostly Factual3h ago
Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
Read full article →YahooMostly Factual1h ago
Merck tops Q1 estimates on strong oncology demand; shares rise
Read full article →Coverage Timeline
First report: cnbc · 30 Apr, 10:32|Full coverage: 3 · 2h|Window: 2h
Left-leaningCenterRight-leaning
